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Second-generation tyrosine kinase inhibitors (TKI2) often induce molecular remission, and prolonged
survival with a better tolerance in imatinib-resistant chronic myelogenous leukaemia (CML) patients.
We report the case of a CML in ﬁrst chronic phase who was diagnosed in August 2003 in a young 24
year-old Caucasian woman. Our patient received ﬁrst imatinib and then dasatinib and nilotinib.
Imatinib was well tolerated and she developed TTP/HUS on dasatinib without documented evolution of
CML and ﬁnally obtained MR5.0 with nilotinib and without any side effect. This case also illustrates the
absence of cross-resistance and side-effects between the different TKIs and the feasibility of kidney
transplantation associated with a nilotinib treatment of CML allowing a continuing MR5.0 and no
further side effects.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Dear Editor,
Second-generation tyrosine kinase inhibitors (TKI2) often
induce molecular remission, and prolonged survival with a better
tolerance in imatinib-resistant chronic myelogenous leukaemia
(CML) patients.1–3 To date, only one case of imatinib-induced
thrombotic thrombocytopenic purpura/haemolytic uraemic
syndrome (TTP/HUS) has been diagnosed in a case of hypereosi-
nophilic syndrome.4 More than 50 drugs have been associated with
the development of TTP5 but no TTP/HUS has been described with
TKI26 yet. We report here the case of an imatinib-resistant CML
presenting terminal renal failure after dasatinib-induced TTP/HUS
and receiving a related renal transplantation on nilotinib.
A CML in ﬁrst chronic phase was diagnosed in August 2003 in a
young 24 year-old Caucasian woman with no prior medical history.
Initial characteristics showed no splenomegaly, a leucocyte count of
22109 /L, with 63% neutrophils, 15% myelemia, no circulating
blast, no anaemia and a normal platelet count. Bone marrow (BM)
aspirate was hypercellular with 1.5% eosinophils, 2.5% basophils,
and 2.5% blasts. Cytogenetic analysis revealed 85% of Philadelphia
chromosome-positive (Phþ) cells and quantitative PCR Bcr-Abl
fusion transcript ratioIS (International Scale)7 was 111%. Sokal score
was low, 0.57 and Hasford score was low, 0. First line imatinib
mesylate (400 mg once daily) was initiated in October 2003 and
well tolerated. A major molecular response (MMR or MR3.0) was
obtained in February 2004 and maintained during almost 2 years
(Fig. 1). In May 2006, we observed a loss of MMR without Abl
mutations detected; imatinib was increased at 600 mg/day but
failed to induce permanent MMR. In January 2008, imatinib was
switched to a TKI2 treatment with dasatinib 100 mg daily and
further MMR was achieved in a few weeks (Fig. 1). The patient did
not take any other medication than dasatinib.
In June 2008, TTP/HUS was diagnosed during hospitalisation in
intensive care unit. Clinical and biological presentation was an
association of thrombocytopenia, microangiopathic haemolytic-NC-ND license.regenerative anaemia, neurological symptoms (Glasgow coma
scale score of 6) requiring intubation and respiratory assistance,
acute renal failure with anuria, fever and abdominal pain. We did
not notice pulmonary arterial hypertension, QTc prolongation,
pericardial effusion, cardiac dysfunction or arrhythmia. Laboratory
evaluations showed a 10 N serum lactate dehydrogenase (LDH)
level, an elevated indirect bilirubinemia level, 50% decreased in
serum haptoglobin level, presence of schizocytes on peripheral
blood smears (0.5–3%), platelet count 64109 /l, leucocytes count
18.7109 /l, urea 27.7 mmol/l, creatinine (Cr) 703 mmol/l, creati-
nine clearance (Cr Cl)o10 ml/min, proteinuria 1,5 g/24 h. Bone
marrow examination conﬁrmed the absence of acceleration or
blast crisis. No sign of coagulation dysfunction was noted. Lumbar
puncture was sterile and proteinorachy was 0.57 g/l. No source of
infection was found except for urinalysis positive to multisensible
streptocoque treated with Ceftriaxone. Complement fractions were
normal. Brain MRI and renal ultrasound were normal. Plasma
ADAMTS13 activity level was 61%; in France, plasma ADAMTS13
activity level was checked in a reference national laboratory and
the normal range is between 50% and 150%. No anti-ADAMTS 13
antibodies were detected. Lymphocytes count at the onset of TTP
was 0.9109 /l and IgH/TCR clonality was not performed. Percu-
taneous renal biopsy was congruent with acute tubular necrosis
and TTP. The plasma level of dasatinib was not checked but
dasatinib was discontinued and a series of 11 plasma exchanges
was performed with corticosteroids, blood transfusions and
haemodialysis.
At day þ10, patient was discharged from intensive care unit to
renal department (from June13rd to July 15th 2008) with less
neurological troubles (persistence of few hallucinations and space-
time disorientation) and no recovery of renal failure (creatinine
617 mmol/l). Persistence of anaemia (8 g/dl) with 2.7% schizocytes
on peripheral smears, low level haptoglobin, 2 N increased
LDH and normalized platelet count. CML was still in MMR as
Fig. 1. Follow-up of BCR/ABL1 transcripts assessed by RT-qPCR. Results are expressed in % according the International Scale (IS). (n) represent ABL mutations analysis.
Arrow indicate time of renal allotransplantation.
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on haemodialysis until 06/07/2008 and then restored sponta-
neous diuresis with persistent renal failure (Cr 525 mmol/l, Cr Cl
15 ml/min). The patient was discharged at day þ28 from renal
department with platelets in normal range (250 G/l) and no
neurological symptoms.
Nilotinib 400 mg daily was ﬁrst introduced in September 2008
and then increased to 600 mg daily in October 2010. We did not use
any prophylactic antithrombotic treatment. Before the onset of
nilotinib, clearance of creatinine was still low (15 ml/min) and low
molecular weight heparins were not indicated. We did not use oral
anticoagulant because of possible interactions with nilotinib and the
low recovery of platelets counts. CML evaluation before nilotinib
introduction showed a Bcr-Abl/Abl ratio of 41% in blood without
loss of CHR and BCR-Abl domain mutation. Given the level of BCR
ABL transcript in blood before the onset of nilotinib, a cytogenetic
relapse is highly probable but no bone marrow aspiration was
performed at this time. On nilotinib treatment, a two (0.82%) and
three (0.08%) log reduction in Bcr-Abl/Abl ratios (IS) at 3 and
6 months respectively were observed with a complete cytogenetic
response in BM. In March 2010, laboratory analyses showed an
haemoglobin level of 12.3 g/dl and a platelet count of 198109 /l.
At latest follow-up (July 2012), the patient was in MR5.0.
Progressive aggravation of renal function occurred between July
2008 and April 2011, Cr Clo15 ml/min and proteinuria (4 g/24 h)
requiring peritoneal dialysis (PD) since May 2011. Finally, PD failed
in June 2011 and in November 2011 we performed a kidney
transplantation from a living related donor (her mother).Immunosuppressive regimen was composed of basiliximab
(20 mg daily during 5 days), tacrolimus (0.15 mg/kg), mycofenolate
mofetil (3 g daily) and corticosteroids (5 mg/kg). No recurrence of
TTP/HUS occurred during kidney transplantation procedure despite
the use of anticalcineurin (tacrolimus) and no other complication
was reported. Currently, post-transplant renal function is stabilized
at 123 mmol/l (Cr Cl 45 ml/min) with on-going immunosuppression
(tacrolimus, mycophenolate mofetil); CML remains in continuous
MR5.0 with nilotinib 300 mg twice daily that is well tolerated.
The transient loss of MMR just before and after renal transplant is
probably due to an irregular oral intake of nilotinib by the patient.
Dasatinib is a TKI2 highly effective in imatinib-resistant CML.1,3
Even if metabolism of this TKI2 is largely hepatic-dependent via
CYP450 CYP3A4, few reports suggest its possible implication in
acute renal failure.6 Our patient received ﬁrst imatinib and then
dasatinib and nilotinib. Imatinib was well tolerated and she devel-
oped TTP/HUS on dasatinib without documented evolution of CML
and ﬁnally obtained MR5.0 with nilotinib and without any side
effect. Direct implication of CML in the occurrence of TTP/HUS is
unlikely because MMR was achieved on dasatinib before the
occurrence of the ﬁrst renal failure episode. Imatinib and nilotinib
have equivalent proﬁles of kinase-inhibition (Abl kinases, c-kit,
PDGF-Receptor) and few reports showed partial resolution of renal
dysfunction through the dissipation of ﬁbrosis in chronic kidney
disease.8 The mechanism implicated is mediated by PDGF-R inhibi-
tion. Renal failure was already described in very few cases of
imatinib treated patients and often reversible.9,10 Activity of dasa-
tinib is quite different with an enhanced inhibition spectrum to Scr-
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TTP are unknown. The medical history of the patient suggests that
Abl kinase inhibition is not directly implicated in the dasatinib
induced TTP/HUS. Temporal association between the initiation of
dasatinib treatment and the development of TTP/HUS and the level
of plasma ADAMTS13 activity level suggest a possible auto-immune
mechanismmore than a dose-related dasatinib toxicity. We suggest
that the mechanism by which dasatinib may lead to a TTP/HUS is a
direct endothelial toxicity. Dasatinib activated leucocytes adhered
to endothelial cells and an adhesion mediated lysis of these cells
occurred with an alteration of activity and metabolism of vWF and
platelet aggregation, resulting in TTP/HUS.11
To our knowledge it is the ﬁrst report of a dasatinib TTP/HUS
with terminal renal failure. This case also illustrates the absence of
cross-resistance and side-effects between the different TKIs and
the feasibility of kidney transplantation associated with a nilotinib
treatment of CML allowing a continuing MR5.0 and no further side
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